To the annoyance of some shareholders, Shanghai Medicilon Inc. (SHSE:688202) shares are down a considerable 27% in the last month, which continues a horrid run for the company. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 71% loss during that time.
After such a large drop in price, considering around half the companies operating in China’s Life Sciences industry have price-to-sales ratios (or “P/S”) above 5.1x, you may consider Shanghai Medicilon as an solid investment opportunity with its 3.2x P/S ratio. However, the P/S might be low for a reason and it requires further investigation to determine if it’s justified.
View our latest analysis for Shanghai Medicilon
What Does Shanghai Medicilon’s P/S Mean For Shareholders?
Shanghai Medicilon could be doing better as its revenue has been going backwards lately while…
